MaraverLab

This work was possible thanks to a fantastic group of colleagues from @ircm-mtp.bsky.social @ICM_Montpellier @umontpellier.bsky.social
@goteborgsuni @cniostopcancer.bsky.social @CIMA_unav @H12Octubre @nyulangone Thanks a lot to all our great collaborators!! Together we are stronger!!!

This work was possible thanks to a fantastic and complementary group of colleagues from @IRCM_MTP @ICM_Montpellier @umontpellier @goteborgsuni @CNIOStopCancer @CIMA_unav @H12Octubre @nyulangone Thanks a lot to all our great collaborators!! Together we are stronger!!!

As you know, ferroptosis inhibitors are still far from being used in the
clinic, but our findings provide a new way to sensitize cells against them which could
facilitate their clinical translation, at least to treat the leading cause of death by cancer in the
world, i.e., lung.

4. We further dissect the mechanism and uncovered
that FMO4 binds MAT2A, leading to the stabilization of the MAT2A-MAT2B
complex in order to promote the generation of cysteine that in turn regenerates
reduced glutathione to allow GPX4-driven protection against ferroptosis.

2. We demonstrate that FMO is critically required for KRAS-driven lung cancer
generation and maintenance in mice in vivo.
3. We found that FMO4 deletion in lung cancer sensitizes cells against ferroptosis both
in vitro and in vivo, revealing FMO4 as an interesting target in lung cancer.

1. We first found that flavin containing monooxygenase 4
(FMO4) is highly expressed in lung tumors and very low expressed in healthy lung in mouse and lung cancer patients where its expression negatively correlates with patients’ survival.

Thrilled to present our study aiming to identify new vulnerabilities in lung cancer: www.biorxiv.org/content/10.1...
Joining forces from mouse genetics, thoracic oncology,
metabolism, and AlphaFold fields we dissected the role of a largely unknown but essential protein in cancer, FMO4.🧵

Happy to share our latest findings @bloodneoplasia.bsky.social uncovering an ACLY-MYC feedforward loop in T-ALL, led by @dasilva-diz.bsky.social

doi.org/10.1016/j.bn...

it is funny because is true 😂😂

😂

On my way to the 20th annual meeting Cancéropôle
Grand Sud-Ouest to enjoy 2 days fully charged of super cool science!! Like in previous editions, we have fantastic national and international speakers and our lab will present several cool studies so stay tuned 😀

We are looking for our future colleagues. IRCM (www.ircm.fr) host labs studying cancer biology from basic to translational research. Montpellier has a thriving and very dynamic scientific life. Please forward to potential candidates.

Graphic titled "If you have lungs, you can get lung cancer."

November is Lung Cancer Awareness Month. One simple truth: if you have lungs, you can get lung cancer. In fact, 1 in 16 people will receive a #LungCancer diagnosis in their lifetime. Spread the word! Visit LCRF.org/LCAM to learn how. #LCAM2024

I cannot think a better way to start our communication in bsky than promoting the Lung Cancer Awareness Month (LCAM) with our commitment to tackle this deadly disease. And to remind you: "if you have lungs, you can have lung cancer" @lungcancerresearch.bsky.social and many more not yet @bsky.app